MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
Summarize this article with:
This section is Partnership Content suppliedThe content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Article contentNEW YORK — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that Rob Barrow, Chief Executive Officer, will present at the 44th Annual J.P.
Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 2:15 p.m. PT.Sign In or Create an AccountEmail AddressContinueor View more offersArticle content“It is a privilege to participate in the J.P.
Morgan Healthcare Conference as we continue to share the progress MindMed is making to forge a new era of psychiatry,” said Rob Barrow, Chief Executive Officer. “The conference provides a meaningful opportunity to engage with the investment community as we prepare for a defining year ahead with three anticipated Phase 3 topline readouts, advancing toward potential FDA submissions in two of the largest psychiatry markets, GAD and MDD.”Article contentWe apologize, but this video has failed to load.Try refreshing your browser, ortap here to see other videos from our team.Article contentArticle contentA live audio webcast will be available to investors and other interested parties and can be accessed here.Article contentTop StoriesGet the latest headlines, breaking news and columns.There was an error, please provide a valid email address.Sign UpBy signing up you consent to receive the above newsletter from Postmedia Network Inc.Thanks for signing up!A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againInterested in more newsletters? Browse here.Article contentThe audio webcast replay will be available 24 hours after the webcast and active on MindMed’s website for 30 days.Article contentAbout MindMedArticle contentMindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health.Article contentMindMed trades on NASDAQ under the symbol MNMD.Article contentArticle contentArticle contentArticle contentView source version on businesswire.com: Article content https://www.businesswire.com/news/home/20251218657589/en/Article contentArticle contentContactsArticle contentFor further information, please contact:Article contentInvestors: Article contentArticle contentGitanjali JainArticle contentArticle contentVP, Head of Investor RelationsArticle contentArticle contentir@mindmed.coArticle contentMedia: Article contentArticle contentmedia@mindmed.coArticle content#distroArticle contentTrending Trump Official Signals Support for Trade Deal With Canada, Mexico PMN Business Is a $2.75 million portfolio enough for Halifax empty nesters to retire early?
Personal Finance World watches as Ottawa's bullish shift on LNG puts wind at the back of two major projects Oil & Gas So long, labour shortage: job vacancies continue to decline in Canada Work Canada's population declines for the first time since the pandemic News Share this article in your social networkCommentsYou must be logged in to join the discussion or read more comments.Create an AccountSign in Join the Conversation Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information.
Trump Official Signals Support for Trade Deal With Canada, Mexico PMN Business Is a $2.75 million portfolio enough for Halifax empty nesters to retire early?
Personal Finance World watches as Ottawa's bullish shift on LNG puts wind at the back of two major projects Oil & Gas So long, labour shortage: job vacancies continue to decline in Canada Work Canada's population declines for the first time since the pandemic News